Association of Baseline Metastatic Tumor Estrogen Receptor (ER) α and Aurora A Kinase (AURKA) Expression and Progression-Free Survival (PFS)
METASTATIC TUMOR
Formalin-fixed and paraffin-embedded metastatic tumor tissue blocks were sectioned and stained using antibodies against ERα or total AURKA. A log-rank test and Cox modeling were used to assess whether PFS differed regarding pretreatment metastatic tumor ERα expression of 10% or greater or AURKA expression less than 10%. A, Arm 1 (alisertib monotherapy): ERα. B, Arm 2 (alisertib + fulvestrant): ERα. C, Arm 1 (alisertib monotherapy): AURKA. D, Arm 2 (alisertib + fulvestrant): AURKA.